CYTK Cytokinetics, Incorporated - Common Stock

NASDAQ · Biotechnology · View on SEC EDGAR ↗
$76.68
Price · Aug 19, 2026
Fundamentals as of Aug 6, 2026
52W Range
$35–$88
78% of range
Analyst Rating
BUY
28 analysts
Price Target
$110
+43% upside
P/E (TTM)
-11.7
ROE
152.7%
Net Profit Margin
-891.6%

About Cytokinetics, Incorporated - Common Stock Company overview from Wikipedia

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

Read more

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

History

Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.

Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.

In 2004 the company completed its initial public offering (IPO).

In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.

In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.

In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.

Products

Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.

Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.

Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

CYTK Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$76.67
Market Cap
$9.43B
P/E (TTM)
-11.7
EPS (TTM)
$-6.54
Revenue (TTM)
$88M
Div Yield
—
ROE
152.7%
Debt/Equity
-0.4
52W Range
$35 – $88

CYTK Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income $88M
10-point trend, -17.3%
2016-12-31 → 2025-12-31
EPS $-6.54
8-point trend, -1776.9%
2016-12-31 → 2025-12-31
Free Cash Flow $-535M
10-point trend, -1611.4%
2016-12-31 → 2025-12-31
Margins -891.6%

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
CYTK
Peer Median
P/E (TTM)
5-point trend, +40.3%
-11.7
28.5
P/S (TTM)
5-point trend, +61.7%
107.1
20.1
P/B
5-point trend, -174.7%
-14.3
12.9
EV / EBITDA
5-point trend, +35.8%
-15.9
—
Price / FCF
5-point trend, +27.7%
-17.6
—

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
CYTK
Peer Median
Operating Margin
5-point trend, -162.9%
-695.4%
—
Net Profit Margin
5-point trend, -191.6%
-891.6%
-48.4%
ROA
5-point trend, -77.4%
-55.5%
-28.4%
ROE
5-point trend, +274.7%
152.7%
-49.2%

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
CYTK
Peer Median
Debt / Equity
5-point trend, -324.5%
-0.4
—
Current Ratio
5-point trend, -39.2%
4.5
5.0
Quick Ratio
5-point trend, -69.7%
0.7
—

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
CYTK
Peer Median
Revenue YoY
5-point trend, +25.0%
376.6%
—
Revenue CAGR 3Y
5-point trend, +25.0%
-2.4%
—
Revenue CAGR 5Y
5-point trend, +25.0%
9.5%
—

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
CYTK
Peer Median
EPS (Diluted)
5-point trend, -133.6%
$-6.54
—

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
CYTK
Peer Median

CYTK Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 28 analysts
  • Strong Buy 6 21.4%
  • Buy 19 67.9%
  • Hold 3 10.7%
  • Sell 0 0.0%
  • Strong Sell 0 0.0%

12-Month Price Target

20 analysts · 2026-08-18
Median target $107.50 +40.2%
Mean target $109.90 +43.3%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
-0.08%
Period EPS Actual EPS Est Surprise
June 30, 2026 $-1.50 $-1.67 0.17%
March 31, 2026 $-1.67 $-1.69 0.02%
Dec. 31, 2025 $-1.50 $-1.49 -0.01%
Sept. 30, 2025 $-2.55 $-1.61 -0.94%
June 30, 2025 $-1.12 $-1.41 0.28%
March 31, 2025 $-1.39 $-1.41 0.02%

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
CYTK $7.81B -9.7 376.6% -891.6% 152.7% —
ARWR $4.68B -3449.0 23258.2% -0.20% -0.50% —
MDGL $13.30B -45.3 432.1% -30.1% -44.4% —
HALO $7.93B 26.3 37.5% 22.7% 166.1% —
PRAX $7.43B -21.9 249.5% — -47.3% —
APGE $5.16B -17.9 — — — —
PTGX $5.47B -42.6 -89.4% -282.8% -20.3% —
KRYS $7.20B 36.0 33.9% 52.6% 18.1% —
KYMR $6.33B -21.1 -16.7% -794.0% -24.4% —
SMMT $13.56B -12.1 — — -235.1% —

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Income Statement 16
Annual Income Statement data for CYTK
Metric Trend 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +87.6% $88M $18M $8M $95M $70M $56M $27M $32M $13M $106M $29M $47M
R&D Expense 12-point trend, +836.4% $416M $339M $330M $241M $160M $97M $86M $89M $90M $60M $46M $44M
SG&A Expense 12-point trend, +1546.2% $284M $215M $174M $178M $97M $53M $40M $31M $36M $28M $20M $17M
Operating Expenses 12-point trend, +1035.1% $700M $555M $504M $419M $257M $150M $126M $120M $127M $88M $66M $62M
Operating Income 12-point trend, -4049.8% $-612M $-536M $-496M $-324M $-186M $-94M $-99M $-89M $-113M $19M $-37M $-15M
Interest Expense 12-point trend, +45579000.00 $46M $38M $28M $19M $16M $16M $7M $4M $3M $3M $268.0K $0
Interest Income 8-point trend, +11187.1% · · · $11M $1M $5M $4M $4M · $449.0K $156.0K $101.0K
Other Non-op 12-point trend, +44733.3% $48M $52M $28M $11M $331.0K $5M $5M $4M $3M $464.0K $174.0K $108.0K
Pretax Income 5-point trend, -625.7% · · · · · · · $-106M $-128M $16M $-38M $-15M
Income Tax Flat — no change across 12 periods $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0
Net Income 12-point trend, -5259.5% $-785M $-590M $-526M $-389M $-215M $-127M $-122M $-106M $-128M $16M $-38M $-15M
EPS (Basic) 10-point trend, -1495.1% $-6.54 $-5.26 $-5.45 $-4.33 $-2.80 $-1.97 · · $-2.59 $0.41 $-0.97 $-0.41
EPS (Diluted) 10-point trend, -1495.1% $-6.54 $-5.26 $-5.45 $-4.33 $-2.80 $-1.97 · · $-2.59 $0.39 $-0.97 $-0.41
Shares (Basic) 10-point trend, -99.7% 120,103 111,979 96,524 89,825 76,886 64,524 · · 49,404,000 39,943,000 38,814,000 35,709,000
Shares (Diluted) 10-point trend, -99.7% 120,103 111,979 96,524 89,825 76,886 64,524 · · 49,404,000 42,561,000 38,814,000 35,709,000
EBITDA 12-point trend, -4121.3% $-602M $-527M $-484M $-318M $-184M $-92M $-98M $-88M $-111M $19M $-37M $-14M
Balance Sheet 26
Annual Balance Sheet data for CYTK
Metric Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +506.1% $123M $95M $113M $66M $113M $83M $36M $42M $125M $67M $65M $20M
Receivables 10-point trend, +73916.7% $18M $17M $1M $147.0K $52M $4M $5M $2M $1M $24.0K · ·
Inventory $0 · · · · · · · · · · ·
Prepaid Expense 12-point trend, +1251.6% $17M $15M $12M $12M $12M $6M $3M $2M $4M $2M $2M $1M
Other Current Assets · · · · · · · · · · · $1M
Current Assets 12-point trend, +599.3% $917M $1.11B $628M $795M $536M $474M $234M $208M $274M $159M $113M $131M
PP&E (Net) 12-point trend, +4737.8% $79M $66M $69M $80M $73M $13M $5M $3M $4M $4M $2M $2M
PP&E (Gross) 12-point trend, +475.9% $126M $103M $97M $98M $89M $38M $29M $27M $26M $25M $23M $22M
Accum. Depreciation 12-point trend, +132.7% $47M $37M $28M $17M $16M $25M $24M $24M $23M $21M $21M $20M
Other Non-current Assets 11-point trend, +8570.5% $17M $8M $8M $10M $7M $6M · $300.0K $429.0K $200.0K $200.0K $200.0K
Total Assets 12-point trend, +971.3% $1.42B $1.40B $824M $1.01B $841M $534M $290M $211M $295M $170M $115M $133M
Accounts Payable 12-point trend, +1541.2% $22M $20M $22M $26M $21M $8M $8M $4M $5M $4M $2M $1M
Accrued Liabilities 12-point trend, +1442.2% $83M $55M $43M $44M $34M $19M $12M $16M $17M $18M $8M $5M
Current Liabilities 12-point trend, +748.7% $202M $180M $103M $85M $72M $31M $26M $22M $32M $33M $32M $24M
Capital Leases 8-point trend, +13903.9% $108M $113M $120M $127M $112M $440.0K $2M $771.0K · · · ·
Other Non-current Liabilities 8-point trend, -100.0% · $0 $186.0K $1M $4M $0 · $771.0K $1M $142.0K · ·
Total Liabilities 12-point trend, +4995.3% $2.08B $1.54B $1.21B $1.12B $597M $420M $301M $185M $185M $76M $47M $41M
Long-term Debt 10-point trend, +1864.4% $288M $620M $639M $650M · $46M $45M $42M $32M $30M $15M ·
Total Debt 11-point trend, +1864.4% $288M $105M $68M $64M $47M $46M $45M $42M $32M $30M $15M ·
Common Stock 12-point trend, +215.4% $123.0K $118.0K $102.0K $94.0K $84.0K $70.0K $59.0K $55.0K $54.0K $41.0K $40.0K $39.0K
Paid-in Capital 2-point trend, +146.5% · · · · $1.45B · · · · · · $589M
Retained Earnings 12-point trend, -601.2% $-3.49B $-2.70B $-2.11B $-1.59B $-1.21B $-992M $-865M $-743M $-646M $-518M $-535M $-497M
AOCI 12-point trend, +15850.0% $630.0K $2M $-10.0K $-4M $-869.0K $149.0K $679.0K $500.0K $343.0K $137.0K $149.0K $-4.0K
Stockholders' Equity 12-point trend, -816.5% $-660M $-135M $-386M $-108M $244M $113M $-11M $26M $110M $94M $69M $92M
Liabilities + Equity 12-point trend, +971.3% $1.42B $1.40B $824M $1.01B $841M $534M $290M $211M $295M $170M $115M $133M
Shares Outstanding 12-point trend, +218.0% 122,943,172 118,209,139 101,637,922 94,833,975 84,799,542 71,015,183 59,172,124 54,717,906 53,960,832 40,646,595 39,581,692 38,659,738
Cash Flow 16
Annual Cash Flow data for CYTK
Metric Trend 202520242023202220212020201920182017201620152014
D&A 12-point trend, +1966.3% $10M $10M $12M $6M $2M $2M $1M $1M $2M $741.0K $589.0K $490.0K
Stock-based Comp 12-point trend, +3272.0% $112M $98M $72M $48M $27M $18M $11M $10M $9M $7M $5M $3M
Deferred Tax Flat — no change across 3 periods · · · · · · · · · $0 $0 $0
Restructuring · · · · · · · · · · · $0
Other Non-cash 12-point trend, +548.4% $153M $86M $28M $36M $44M $117M $19M $-6M $15M $13M $37M $-34M
Operating Cash Flow 12-point trend, -1037.3% $-510M $-396M $-414M $-300M $-143M $9M $-91M $-101M $-102M $37M $5M $-45M
CapEx 12-point trend, +2147.0% $25M $4M $1M $11M $49M $11M $3M $889.0K $3M $2M $562.0K $1M
Investing Cash Flow 9-point trend, +125.3% $17M $-553M $239M $-262M $-148M $-197M $-75M $5M $-66M · · ·
Net Debt Issued 3-point trend, +77.3% $-11M $-9M · $-48M · · · · · · · ·
Stock Issued 9-point trend, +235.4% · · $164M · $0 $0 $36M $0 $112M $0 $9M $49M
Net Stock Activity 9-point trend, +235.4% · · $164M · $0 $0 $36M $0 $112M $0 $9M $49M
Financing Cash Flow 9-point trend, +132.1% $524M $931M $221M $516M $320M $234M $160M $13M $226M · · ·
Net Change in Cash 12-point trend, +53233.3% $30M $-18M $46M $-45M $30M $47M $-6M $-83M $58M $2M $45M $57.0K
Taxes Paid 8-point trend, -100.0% $0 $0 $0 · · · · $1.0K $1.0K $1.0K $1.0K $1.0K
Free Cash Flow 12-point trend, -1064.0% $-535M $-400M $-416M $-311M $-191M $-2M $-94M $-102M $-105M $35M $4M $-46M
Levered FCF 4-point trend, -130.5% · · · · · · · $-106M $-108M $33M · $-46M
Profitability 7
Annual Profitability data for CYTK
Metric Trend 202520242023202220212020201920182017201620152014
Operating Margin 12-point trend, -2112.7% -695.4% -2902.7% -6589.7% -342.8% -264.5% -168.3% -368.0% -282.3% -848.3% 17.6% -130.5% -31.4%
Net Margin 12-point trend, -2757.7% -891.6% -3191.1% -6988.6% -411.2% -305.7% -228.0% -452.9% -337.4% -955.9% 15.5% -130.9% -31.2%
Pretax Margin 5-point trend, -981.4% · · · · · · · -337.4% -955.9% 15.5% -130.9% -31.2%
EBITDA Margin 12-point trend, -2150.5% -683.9% -2851.1% -6431.8% -336.6% -261.3% -165.0% -363.2% -278.3% -833.9% 18.3% -128.5% -30.4%
ROA 12-point trend, -310.0% -55.5% -53.0% -57.2% -41.9% -31.3% -30.9% -48.6% -42.0% -55.0% 11.5% -30.2% -13.6%
ROE 12-point trend, +863.7% 152.7% 789.8% 127.6% 628.0% -87.4% -96.8% 790.0% -272.5% -125.2% 20.2% -46.7% -20.0%
ROIC 5-point trend, -711.5% · · · · · · · -130.1% -80.1% 15.0% -44.9% -16.0%
Liquidity & Solvency 5
Annual Liquidity & Solvency data for CYTK
Metric Trend 202520242023202220212020201920182017201620152014
Current Ratio 12-point trend, -17.6% 4.5 6.2 6.1 9.4 7.5 15.2 9.0 9.4 8.5 4.8 3.6 5.5
Quick Ratio 12-point trend, -18.2% 0.7 0.6 1.1 0.8 2.3 2.8 1.6 2.0 3.9 2.0 2.1 0.8
Debt / Equity 11-point trend, -304.3% -0.4 -0.8 -0.2 -0.6 0.2 0.4 -4.1 1.6 0.3 0.3 0.2 ·
LT Debt / Equity 11-point trend, -275.0% -0.4 -0.7 -0.2 -0.6 0.2 0.4 -4.1 1.5 0.3 0.3 0.2 ·
Interest Coverage 10-point trend, -293.9% -13.4 -14.2 -17.5 -16.7 -11.3 -5.9 -14.9 -23.4 -37.6 6.9 · ·
Efficiency 2
Annual Efficiency data for CYTK
Metric Trend 202520242023202220212020201920182017201620152014
Asset Turnover 12-point trend, -85.7% 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.7 0.2 0.4
Receivables Turnover 9-point trend, -78.3% 5.1 2.1 10.5 3.6 2.5 11.7 7.3 18.8 23.5 · · ·
Per Share 5
Annual Per Share data for CYTK
Metric Trend 202520242023202220212020201920182017201620152014
Book Value / Share 12-point trend, -325.3% $-5.37 $-1.15 $-3.80 $-1.14 $2.88 $1.60 $-0.18 $0.47 $2.04 $2.32 $1.73 $2.38
Revenue / Share 6-point trend, +29220.0% $733.03 $164.98 $78.01 $1053.03 · · · · $0.27 $2.50 · ·
Cash Flow / Share 6-point trend, -488813.3% $-4246.43 $-3535.39 $-4292.54 $-3334.44 · · · · $-2.06 $0.87 · ·
Cash / Share 12-point trend, +90.6% $1.00 $0.80 $1.11 $0.69 $1.33 $1.17 $0.62 $0.77 $2.32 $1.65 $1.64 $0.52
EPS (TTM) 10-point trend, -1495.1% $-6.54 $-5.26 $-5.45 $-4.33 $-2.80 $-1.97 · · $-2.59 $0.39 $-0.97 $-0.41
Growth Rates 3
Annual Growth Rates data for CYTK
Metric Trend 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, +1340.0% 376.6% 145.3% -92.0% 34.3% 26.2% · · · · · · ·
Revenue CAGR 3Y 3-point trend, +95.2% -2.4% -36.0% -48.7% · · · · · · · · ·
Revenue CAGR 5Y 9.5% · · · · · · · · · · ·
Valuation (TTM) 14
Annual Valuation (TTM) data for CYTK
Metric Trend 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +87.6% $88M $18M $8M $95M $70M $56M $27M $32M $13M $106M $29M $47M
Net Income TTM 12-point trend, -5259.5% $-785M $-590M $-526M $-389M $-215M $-127M $-122M $-106M $-128M $16M $-38M $-15M
Market Cap 12-point trend, +2422.7% $7.81B $5.56B $8.49B $4.35B $3.87B $1.48B $628M $346M $440M $494M $414M $310M
Enterprise Value 11-point trend, +2093.9% $7.98B $5.57B $8.44B $4.34B $3.80B $1.44B $636M $346M $346M $457M $364M ·
P/E 10-point trend, +50.3% -9.7 -8.9 -15.3 -10.6 -16.3 -10.5 · · -3.1 31.2 -10.8 -19.5
P/S 12-point trend, +1245.0% 88.7 301.0 1126.9 45.9 54.9 26.4 23.4 11.0 32.9 4.6 14.4 6.6
P/B 12-point trend, -452.1% -11.8 -41.1 -22.0 -40.3 15.8 13.0 -57.4 13.3 4.0 5.2 6.0 3.4
P / Tangible Book 2-point trend, +21.8% · · · · 15.8 13.0 · · · · · ·
P / Cash Flow 12-point trend, -121.8% -15.3 -14.0 -20.5 -14.5 -27.1 165.0 -6.9 -3.4 -4.3 13.4 84.8 -6.9
P / FCF 12-point trend, -116.7% -14.6 -13.9 -20.4 -14.0 -20.2 -699.7 -6.7 -3.4 -4.2 14.0 95.8 -6.7
EV / EBITDA 11-point trend, -34.1% -13.2 -10.6 -17.4 -13.6 -20.6 -15.6 -6.5 -3.9 -3.1 23.5 -9.9 ·
EV / FCF 11-point trend, -117.7% -14.9 -13.9 -20.3 -14.0 -19.9 -682.3 -6.8 -3.4 -3.3 12.9 84.1 ·
EV / Revenue 11-point trend, +614.2% 90.6 301.5 1121.0 45.9 54.0 25.8 23.7 11.0 25.9 4.3 12.7 ·
Earnings Yield 10-point trend, -101.0% -10.3% -11.2% -6.5% -9.4% -6.1% -9.5% · · -31.8% 3.2% -9.3% -5.1%

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Income Statement
2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $88M$18M$8M$95M$70M
Operating Margin % -695.4%-2902.7%-6589.7%-342.8%-264.5%
Net Income $-785M$-590M$-526M$-389M$-215M
Diluted EPS $-6.54$-5.26$-5.45$-4.33$-2.80
Balance Sheet
2025-12-312024-12-312023-12-312022-12-312021-12-31
Debt / Equity -0.4-0.8-0.2-0.60.2
Current Ratio 4.56.26.19.47.5
Quick Ratio 0.70.61.10.82.3
Cash Flow
2025-12-312024-12-312023-12-312022-12-312021-12-31
Free Cash Flow $-535M$-400M$-416M$-311M$-191M

Latest News Recent headlines mentioning this company

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Institutional owners (13F) 539 filers · $9.0B total · As of June 30, 2026

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
104 (+7 vs prior Q) 49 (-8 vs prior Q) 222 (+45 vs prior Q) 112 (-32 vs prior Q) +17.8M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
VANGUARD PORTFOLIO MANAGEMENT LLC $571,778,157 6,711,799 6.37% Shares
STATE STREET CORP $553,243,709 6,494,233 6.16% Shares
VANGUARD CAPITAL MANAGEMENT LLC $521,151,103 6,117,515 5.80% Shares
WELLINGTON MANAGEMENT GROUP LLP $509,521,049 5,980,996 5.68% Shares
Avoro Capital Advisors LLC $425,949,915 4,999,999 4.74% Shares
FMR LLC $375,035,430 4,402,341 4.18% Shares
GEODE CAPITAL MANAGEMENT, LLC $259,207,450 3,042,018 2.89% Shares
BANK OF AMERICA CORP /DE/ $251,706,463 2,954,648 2.80% Shares
RTW INVESTMENTS, LP $243,814,036 2,862,003 2.72% Shares
Polar Capital Holdings Plc $191,988,358 2,253,649 2.14% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $161,060,214 1,890,600 1.79% Call option
Capital Research Global Investors $143,683,584 1,686,625 1.60% Shares
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC $136,597,224 1,603,442 1.52% Shares
Integral Health Asset Management, LLC $136,304,000 1,600,000 1.52% Shares
Point72 Asset Management, L.P. $135,257,185 1,587,712 1.51% Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $133,386,924 1,565,758 1.49% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $131,998,327 1,549,458 1.47% Shares
PRINCIPAL FINANCIAL GROUP INC $111,435,932 1,308,087 1.24% Shares
Capital International Investors $111,245,191 1,305,848 1.24% Shares
ARMISTICE CAPITAL, LLC $106,487,500 1,250,000 1.19% Call option
ARMISTICE CAPITAL, LLC $102,342,325 1,201,342 1.14% Shares
Pictet Asset Management Holding SA $99,038,455 1,160,463 1.10% Shares
Frazier Life Sciences Management, L.P. $98,810,092 1,159,879 1.10% Shares
Holocene Advisors, LP $97,506,685 1,144,579 1.09% Shares
Woodline Partners LP $93,769,315 1,100,708 1.04% Shares
NORGES BANK $86,512,319 1,015,522 0.96% Shares
Royalty Pharma Sub-Manager, LLC $83,519,594 980,392 0.93% Shares
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. $81,937,000 961,815 0.91% Shares
VANGUARD FIDUCIARY TRUST CO $77,218,175 906,423 0.86% Shares
CITADEL ADVISORS LLC $77,062,874 904,600 0.86% Call option
Melqart Asset Management (UK) Ltd $65,385,455 767,525 0.73% Shares
Siren, L.L.C. $64,655,121 758,952 0.72% Shares
Fisher Asset Management, LLC $63,355,547 743,697 0.71% Shares
Foresite Capital Management IV, LLC $60,884,867 714,695 0.68% Shares
Balyasny Asset Management L.P. $60,599,821 711,349 0.67% Shares
Deep Track Capital, LP $59,633,000 700,000 0.66% Shares
JANE STREET GROUP, LLC $59,633,000 700,000 0.66% Call option
BNP PARIBAS FINANCIAL MARKETS $58,702,470 689,077 0.65% Shares
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. $56,251,809 660,310 0.63% Shares
CITADEL ADVISORS LLC $54,601,338 640,936 0.61% Shares
GOLDMAN SACHS GROUP INC $54,053,311 634,503 0.60% Shares
Qube Research & Technologies Ltd $48,774,257 572,535 0.54% Shares
EVENTIDE ASSET MANAGEMENT, LLC $48,081,832 564,398 0.54% Shares
Affinity Asset Advisors, LLC $46,854,500 550,000 0.52% Shares
First Turn Management, LLC $44,930,228 527,412 0.50% Shares
AMERICAN CENTURY COMPANIES INC $44,162,525 518,398 0.49% Shares
Caption Management, LLC $43,651,356 512,400 0.49% Call option
D. E. Shaw & Co., Inc. $40,874,247 479,801 0.46% Shares
Checkpoint Capital L.P. $40,465,250 475,000 0.45% Shares
Hood River Capital Management LLC $39,977,367 469,273 0.45% Shares
RP Management, LLC $39,401,954 980,392 0.44% Shares
EMERALD ADVISERS, LLC $39,013,272 457,956 0.43% Shares
ADAR1 Capital Management, LLC $39,009,097 457,907 0.43% Shares
AMERIPRISE FINANCIAL INC $38,010,006 446,179 0.42% Shares
Candriam S.C.A. $37,708,477 443,066 0.42% Shares
MARSHALL WACE, LLP $36,259,335 425,629 0.40% Shares
RHUMBLINE ADVISERS $35,933,015 421,799 0.40% Shares
CITADEL ADVISORS LLC $35,882,028 421,200 0.40% Put option
ALLIANCEBERNSTEIN L.P. $35,327,299 535,993 0.39% Shares
GILDER GAGNON HOWE & CO LLC $34,096,829 400,245 0.38% Shares
TD Asset Management Inc $32,809,225 385,130 0.37% Shares
BlackRock, Inc. $29,124,928 341,882 0.32% Shares
GSK plc $29,001,573 340,434 0.32% Shares
TWO SIGMA INVESTMENTS, LP $27,040,243 317,411 0.30% Shares
CITIGROUP INC $26,852,314 315,205 0.30% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $24,671,024 289,600 0.27% Put option
Trails Edge Capital Partners, LP $24,542,302 288,089 0.27% Shares
EMERALD MUTUAL FUND ADVISERS TRUST $23,833,521 279,769 0.27% Shares
Polaris Capital Management, LLC $22,737,211 266,900 0.25% Shares
SEGALL BRYANT & HAMILL, LLC $21,899,197 257,063 0.24% Shares
Alyeska Investment Group, L.P. $21,297,500 250,000 0.24% Shares
ExodusPoint Capital Management, LP $21,234,374 249,259 0.24% Shares
Capital World Investors $21,196,550 248,815 0.24% Shares
Walleye Capital LLC $20,422,428 239,728 0.23% Shares
E. Ohman J:or Asset Management AB $19,823,223 300,762 0.22% Shares
Sarissa Capital Management LP $19,476,393 228,623 0.22% Shares
Swiss National Bank $18,946,256 222,400 0.21% Shares
SPHERA FUNDS MANAGEMENT LTD. $18,740,693 219,987 0.21% Shares
BAKER BROS. ADVISORS LP $17,997,836 211,267 0.20% Shares
California Public Employees Retirement System $17,979,520 211,052 0.20% Shares
Nicholas Investment Partners, LP $17,810,758 209,071 0.20% Shares
PINNACLE ASSOCIATES LTD $17,245,864 202,440 0.19% Shares
Mirador Capital Partners LP $17,239,900 202,370 0.19% Shares
Tri Locum Partners LP $16,526,860 194,000 0.18% Shares
PFM Health Sciences, LP $16,329,730 191,686 0.18% Shares
Rock Springs Capital Management LP $16,014,016 187,980 0.18% Shares
PRUDENTIAL FINANCIAL INC $15,933,512 187,035 0.18% Shares
DAFNA Capital Management LLC $14,652,510 171,998 0.16% Shares
Ghisallo Capital Management LLC $14,482,300 170,000 0.16% Shares
Impax Asset Management Group plc $14,056,350 165,000 0.16% Shares
Lombard Odier Asset Management (Europe) Ltd $13,494,096 158,400 0.15% Call option
KINGDON CAPITAL MANAGEMENT, L.L.C. $13,383,349 157,100 0.15% Shares
MANUFACTURERS LIFE INSURANCE COMPANY, THE $13,330,276 156,477 0.15% Shares
JANE STREET GROUP, LLC $12,735,905 149,500 0.14% Put option
SCHRODER INVESTMENT MANAGEMENT GROUP $12,145,719 139,190 0.14% Shares
Retirement Systems of Alabama $11,962,891 140,426 0.13% Shares
MetLife Investment Management, LLC $11,930,519 140,046 0.13% Shares
Polymer Capital Management (HK) LTD $11,777,943 138,255 0.13% Shares
Cinctive Capital Management LP $11,742,419 137,838 0.13% Shares
TUDOR INVESTMENT CORP ET AL $11,279,156 132,400 0.13% Call option

Company insiders 52 insiders · 18 officers · 22 directors

Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Sung Lee EVP, Chief Financial Officer July 1, 2026 M 63,221 0 5 $-5,695,855
Ching Jaw SVP Finance & CFO March 6, 2023 A 87,346 0 0 $0
Sharon Surrey Barbari EVP, Finance & CFO Feb. 28, 2017 F 40,323 0 0 $0
Fady Ibraham Malik EVP Research & Development Aug. 18, 2026 M 153,902 0 22 $-4,429,370
Andrew Callos EVP, Chief Commercial Officer July 30, 2026 M 58,555 0 24 $-15,318,893
Jeffrey Hessekiel Chief Legal & Admin Officer March 15, 2026 A 107,943 0 0 $0
Robert Wong VP, Chief Accounting Officer Dec. 3, 2024 A 18,655 0 0 $0
Brett A Pletcher EVP, Chief Legal Officer Aug. 30, 2024 A 33,140 0 0 $0
Mark A Schlossberg SVP - Legal & General Counsel March 15, 2022 M 103,408 0 0 $0
David Cragg Chief HR & Admin Officer March 7, 2022 F 153,233 0 0 $0
Caryn Gordon Mcdowell GC & Chief Compliance Officer Feb. 27, 2018 A 32,548 0 0 $0
Peter S Roddy SVP Finance & CAO Feb. 27, 2018 A 21,520 0 0 $0
Bradley Paul Morgan SVP Drug Discovery & Early Dev Aug. 31, 2017 M 46,441 0 0 $0
Bonnie Charpentier SVP Regulatory & Compliance Feb. 28, 2017 A 29,004 0 0 $0
Andrew A Wolff SVP & CMO Feb. 28, 2017 A 47,255 0 0 $0
David J Morgans JR EVP-Preclinical R&D Feb. 28, 2011 A 42,000 0 0 $0
Michael Rabson SVP Business Dev/Legal & GC Dec. 18, 2009 M 20,043 0 0 $0
Jay K Trautman VP, Discovery Research Feb. 29, 2008 A 47,896 0 0 $0
Robert Arthur Harrington Director July 15, 2026 A 21,932 0 2 $-248,260
James M Daly Director July 15, 2026 A 3,390 0 0 $0
Edward M. Kaye MD Director July 15, 2026 A 10,434 0 6 $-3,544,372
Nancy Wysenski Director July 15, 2026 A 33,992 0 0 $0
Wendell Wierenga Director July 15, 2026 A 35,563 0 3 $-1,881,925
John T Henderson Director July 15, 2026 A 78,360 0 2 $-2,078,525
Lynne B Parshall Director June 1, 2026 S 15,784 0 3 $-1,000,100
Muna Bhanji Director May 27, 2026 A 26,361 0 0 $0
Robert E Landry Director May 27, 2026 A 10,184 0 0 $0
Wendall Wierenga Director July 15, 2025 A 32,345 0 0 $0
COSTA SANTO J Director May 15, 2024 A 20,600 0 0 $0
Sandford D Smith Director Jan. 2, 2024 A 18,801 0 0 $0
Robert Califf Director Jan. 3, 2022 A 6,003 0 0 $0
GAGE L PATRICK Director Nov. 8, 2021 M 28,932 0 0 $0
Denise Gilbert Director May 20, 2015 J — 0 0 $0
Stephen M Dow Director Jan. 2, 2013 A 1,421,052 0 0 $0
James A Spudich Director May 18, 2011 A 180,600 0 0 $0
Grant A Heidrich III Director Jan. 3, 2011 A 93,755 0 0 $0
Michael Schmertzler Director June 3, 2010 S 4,340,923 0 0 $0
Mark Mcdade Director May 21, 2009 A — 0 0 $0
Charles J Homcy Director May 22, 2008 A — 0 0 $0
William J Rutter Director April 29, 2004 C 172,413 0 0 $0
SEVIN ROSEN FUND VI LP 10% owner April 29, 2004 C 1,615,716 0 0 $0
SRB ASSOCIATES VIII LP 10% owner April 29, 2004 C 771,052 0 0 $0
SRB ASSOCIATES VII LP 10% owner April 29, 2004 C 650,000 0 0 $0
SEVIN ROSEN FUND VIII LP 10% owner April 29, 2004 C 755,631 0 0 $0
Robert I Blum — Aug. 10, 2026 M 377,820 0 19 $-9,702,097
Elisabeth Schnieders — Feb. 28, 2017 A 43,919 0 0 $0
James H Sabry — June 3, 2010 M 0 0 0 $0
SEVIN ROSEN VII AFFILIATES FUND LP — April 29, 2004 C 24,050 0 0 $0
SEVIN ROSEN FUND VII LP — April 29, 2004 C 625,950 0 0 $0
SRB ASSOCIATES VI LP — April 29, 2004 C 1,742,951 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 84 ETFs

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
LFSC · RBB Fund, Inc. 3.16% 43,268 NS May 31, 2026 N-PORT
HRTS · Tema ETF Trust 2.52% 17,069 NS May 31, 2026 N-PORT
PTH · Invesco Exchange-Traded Fund Trust 1.81% 58,136 SH Aug. 8, 2026 Daily
FMED · Fidelity Covington Trust 1.55% 8,262 NS May 31, 2026 N-PORT
GDOC · Goldman Sachs ETF Trust 1.40% 3,663 NS May 31, 2026 N-PORT
JSMD · Janus Detroit Street Trust 1.24% 189,801 NS April 30, 2026 N-PORT
JSML · Janus Detroit Street Trust 0.98% 48,338 NS April 30, 2026 N-PORT
LABU · Direxion Shares ETF Trust 0.94% 76,297 NS April 30, 2026 N-PORT
IBB · iShares Trust 0.75% 874,995 SH Aug. 8, 2026 Daily
BBC · ETFis Series Trust I 0.75% 4,355 NS April 30, 2026 N-PORT
IBBQ · Invesco Exchange-Traded Fund Trust … 0.71% 7,377 SH Aug. 8, 2026 Daily
VTWV · VANGUARD SCOTTSDALE FUNDS 0.64% 102,933 SH Aug. 8, 2026 Daily
IWN · iShares Trust 0.62% 1,099,434 SH Aug. 8, 2026 Daily
FNY · First Trust Exchange-Traded AlphaDE… 0.51% 41,612 NS April 30, 2026 N-PORT
BIB · ProShares Trust 0.47% 4,553 NS May 31, 2026 N-PORT
NUSC · Nushares ETF Trust 0.47% 94,565 NS April 30, 2026 N-PORT
MIDE · DBX ETF Trust 0.41% 178 NS May 29, 2026 N-PORT
DWAS · Invesco Exchange-Traded Fund Trust … 0.37% 21,543 SH Aug. 8, 2026 Daily
XJH · iShares Trust 0.35% 18,349 SH Aug. 8, 2026 Daily
IQSM · New York Life Investments ETF Trust 0.34% 16,959 NS April 30, 2026 N-PORT
VTWO · VANGUARD SCOTTSDALE FUNDS 0.34% 761,130 SH Aug. 8, 2026 Daily
IWM · iShares Trust 0.34% 3,349,200 SH Aug. 8, 2026 Daily
IVOG · VANGUARD ADMIRAL FUNDS 0.33% 72,343 SH Aug. 8, 2026 Daily
VBK · VANGUARD INDEX FUNDS 0.32% 1,797,986 SH Aug. 8, 2026 Daily
IVOO · VANGUARD ADMIRAL FUNDS 0.32% 219,413 SH Aug. 8, 2026 Daily
IJK · iShares Trust 0.32% 429,311 SH Aug. 8, 2026 Daily
ISCG · iShares Trust 0.32% 38,968 SH Aug. 8, 2026 Daily
IVOV · VANGUARD ADMIRAL FUNDS 0.31% 53,623 SH Aug. 8, 2026 Daily
IJH · iShares Trust 0.30% 4,684,495 SH Aug. 8, 2026 Daily
IJJ · iShares Trust 0.29% 317,724 SH Aug. 8, 2026 Daily
FNX · First Trust Exchange-Traded AlphaDE… 0.26% 55,086 NS April 30, 2026 N-PORT
ITWO · ProShares Trust 0.25% 6,062 NS May 31, 2026 N-PORT
RSSL · Global X Funds 0.23% 51,834 NS April 30, 2026 N-PORT
PTMC · Pacer Funds Trust 0.23% 14,028 NS April 30, 2026 N-PORT
MVV · ProShares Trust 0.22% 4,565 NS May 31, 2026 N-PORT
SCHA · SCHWAB STRATEGIC TRUST 0.21% 635,330 NS May 31, 2026 N-PORT
BKMC · BNY Mellon ETF Trust 0.20% 19,862 NS April 30, 2026 N-PORT
ESML · iShares Trust 0.20% 72,711 SH Aug. 8, 2026 Daily
SCHM · SCHWAB STRATEGIC TRUST 0.19% 356,940 NS May 31, 2026 N-PORT
FFSM · FIDELITY COVINGTON TRUST 0.19% 37,821 NS April 30, 2026 N-PORT
VFMO · VANGUARD WELLINGTON FUND 0.17% 40,586 SH Aug. 8, 2026 Daily
ISCB · iShares Trust 0.16% 5,525 SH Aug. 8, 2026 Daily
MIDU · Direxion Shares ETF Trust 0.15% 2,025 NS April 30, 2026 N-PORT
UMDD · ProShares Trust 0.15% 638 NS May 31, 2026 N-PORT
FAD · First Trust Exchange-Traded AlphaDE… 0.15% 11,444 NS April 30, 2026 N-PORT
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0.15% 47,609 NS April 30, 2026 N-PORT
UWM · ProShares Trust 0.15% 4,765 NS May 31, 2026 N-PORT
SMDX · Tidal Trust III 0.15% 2,868 NS April 30, 2026 N-PORT
VB · VANGUARD INDEX FUNDS 0.14% 3,113,794 SH Aug. 8, 2026 Daily
VHT · VANGUARD WORLD FUND 0.14% 333,056 SH Aug. 8, 2026 Daily